Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT04488822
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
40 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE3)
Tenosynovial Giant Cell Tumor
NOT_YET_RECRUITING
NCT06650501
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
300 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Staphylococcus Aureus Endocarditis


Staphylococcus Aureus Septicemia


Staphylococcus Aureus Bacteremia


Staphylococcus Aureus Bloodstream Infection


S. Aureus Bacteremia


S. Aureus Bloodstream Infection
COMPLETED
NCT03901352
Study of Mirogabalin for Central Neuropathic Pain
300 Enrollment(s)
118 Study location(s)
INTERVENTIONAL (PHASE3)
Central Neuropathic Pain
COMPLETED
NCT02612649
Special Drug Use Surveillance of Irribow in Female Patients
793 Enrollment(s)
34 Study location(s)
OBSERVATIONAL (None)
Diarrhea-predominant Irritable Bowel Syndrome
NOT_YET_RECRUITING
NCT06630130
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
50 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Stomach Neoplasms
COMPLETED
NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
672 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE2)
Hypertension
NOT_YET_RECRUITING
NCT06585969
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
504 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic Breast Cancer


ER-positive Breast Cancer


Luminal B


Her2 Enriched


Basal Like
ACTIVE_NOT_RECRUITING
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
1,600 Enrollment(s)
482 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-Positive Primary Breast Cancer


Residual Invasive Breast Cancer